3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Multiple Myeloma
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Carcinoma, Non-Small-Cell Lung
6
Neoplasm, Residual
3
Neoplasm Metastasis
3
Leukemia, Myeloid, Acute
3
Neoplasms
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Colorectal Neoplasms
2
Uterine Cervical Neoplasms
1
Smoldering Multiple Myeloma
1
Recurrence
1
Pancreatic Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Plasma Cell
1
Nasopharyngeal Carcinoma
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lung Neoplasms
1
Leukemia, Promyelocytic, Acute
1
Leukemia, Plasma Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Glioma
1
Fallopian Tube Neoplasms
1
Interventions
Gemcitabine
30
Mitomycin
25
BCG Vaccine
11
Docetaxel
10
Epirubicin
6
erdafitinib
5
durvalumab
5
Radiotherapy
5
dodecyl maltoside
4
apaziquone
4
tislelizumab
3
Cystoscopy
3
ALT-803
3
viscum album peptide
2
pembrolizumab
2
disitamab vedotin
2
avelumab
2
VB4-845
2
Therapeutics
2
Imiquimod
2
Hyaluronic Acid
2
5-aminolevulinic acid hexyl ester
2
1-phenyl-3,3-dimethyltriazene
2
vocimagene amiretrorepvec
1
valrubicin
1
tremelimumab
1
toripalimab
1
pirarubicin
1
pemigatinib
1
monalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Non-Muscle Invasive Bladder Neoplasms
×
Maintenance
×
Clear all
NCT07207824
2025-10-06
HERO
Fudan University
Phase 3
Not yet recruiting
182 enrolled